Page 30«..1020..29303132..4050..»

Category Archives: Mesenchymal Stem Cells

Stem cell, regenerative medicine policies to be discussed at Rice's Baker Institute

Posted: Published on October 16th, 2014

Dr. Deepak Srivastava, a leading biomedical research policy expert, will discuss "Stem Cells, Regenerative Medicine and Policy Impediments to the New Future" at Rice University's Baker Institute for Public Policy Oct. 21. The event is free and open to the public, but registration is required. Who: Dr. Deepak Srivastava, the Baker Institute's nonresident scholar for biomedical research policy and the Younger Family Director and senior investigator at the Gladstone Institute of Cardiovascular Disease. Neal Lane, the Malcolm Gillis University Professor, senior fellow in science and technology policy at Rice's Baker Institute for Public Policy and a professor of physics and astronomy, will give introductory remarks. Stem cells and regenerative medicine are exciting and emerging fields of biomedical research, according to event organizers. Proposed applications include treating conditions such as blindness, diabetes and heart disease. Regenerative medicine could also help heal failing organ systems and replace damaged tissue. While these fields hold great promise for medicine, external factors limit and, in some cases, stall research, organizers said. Ethical controversies surrounding human embryonic stem cells, policy issues affecting federal and state funding and regulation, and economic pressures all play a role in determining the future of research. In his presentation, Srivastava will … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Stem cell, regenerative medicine policies to be discussed at Rice's Baker Institute

Discovery of Repair Process After Heart Attack Suggests Potential for New Treatment Strategy

Posted: Published on October 16th, 2014

Contact Information Available for logged-in reporters only Newswise In a study that could point the way toward a new strategy for treating patients after a heart attack, UCLA stem cell researchers led by associate professor of medicine (cardiology) and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research member Dr. Arjun Deb have discovered that some scar-forming cells in the heart, known as fibroblasts, have the ability to become endothelial cells (the cells that form blood vessels). The UCLA team also found that a drug could enhance this phenomenon and improve the repair process after a heart attack. The findings are reported in the October 15, 2014 edition of the journal Nature. It is well known that increasing the number of blood vessels in the injured heart following a heart attack improves its ability to heal, said Dr. Deb, the studys senior author. We know that scar tissue in the heart is associated with a poorer prognosis. Reversing or preventing scar tissue from forming has been one of the major challenges of cardiovascular medicine. Heart disease remains a leading cause of death in the United States. Each year in this country, approximately 720,000 people experience a heart … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Discovery of Repair Process After Heart Attack Suggests Potential for New Treatment Strategy

Stem Cell Therapy For ALS Gets FDA's Fast Track Designation

Posted: Published on October 15th, 2014

By C. Rajan, contributing writer The U.S. FDA has just granted BrainStorm Cell Therapeutics novel stem cell therapy, NurOwn, Fast Track status for the treatment of amyotrophic lateral sclerosis (ALS), the company announced via press release. "We are pleased that the FDA has granted Fast Track status for NurOwn as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS," said Tony Fiorino, MD, PhD, CEO of BrainStorm. "We expect Fast Track designation, which recognizes the potential of NurOwn as to address an unmet medical need in ALS, to help speed and improve our development program." Israeli biotech company BrainStorm is developing novel adult stem cell technologies for neurodegenerative diseases, such as ALS. The company licensed the exclusive rights to the NurOwn technology from Ramot, the technology transfer company of Tel Aviv University. NurOwn is a personalized stem cell product made from autologous mesenchymal stem cells. These adult stem cells are obtained from the patients bone marrow and are induced to secrete neurotrophic factors, which are growth factors that can stimulate the survival and maintenance of neurons that degenerate in neurologic disorders. NurOwn … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Stem Cell Therapy For ALS Gets FDA's Fast Track Designation

Mesenchymal stem cell therapy in treatment of erectile …

Posted: Published on October 13th, 2014

OBJECTIVE: To compare the efficacy of intracavernosal injection of autologous and allogeneic mesenchymal stem cells as potential treatment of erectile dysfunction in an experimental rat model. Mesenchymal stem cells were isolated from rat paratesticular fat tissue. Bilateral cavernous nerve injury was carried out followed by immediate intracavernosal injection of either autologous or allogeneic mesenchymal stem cells or mesenchymal stem cell lysates. One month after injection, erectile function was evaluated by means of intracavernosal pressure measurement. All rats were eventually killed, and penile tissues were taken for immunhistochemical and molecular investigation. A total of 36 Sprague-Dawley rats were used. The mean maximum intracavernosal pressure in the sham-operated, autologous and allogeneic mesenchymal stem cell injection groups were significantly better compared with the vehicle injection group (80.5 [3.56], 71.1 [2.9] and 69.2 [3.2] vs 40.33 [4.4], respectively). Mean maximum intracavernosal pressure to mean arterial pressure ratios in the autologous and allogeneic mesenchymal stem cell and mesenchymal stem cell lysate injection groups were not significantly different. Intracavernosal injection of both autologous or allogeneic mesenchymal stem cells improve erectile functions in a rat model of cavernous nerve injury. Allogeneic mesenchymal stem cells might provide clinicians with ready to use, standardized and, in certain cases, more … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Mesenchymal stem cell therapy in treatment of erectile …

Human Mesenchymal Stem Cells & Media

Posted: Published on October 10th, 2014

Bone marrow contains a population of rare progenitor cells known as Mesenchymal Stem Cells (MSC) capable of replication as undifferentiated cells or differentiating into bone, cartilage, fat, muscle, tendon and marrow stroma. Due to the nature of mesenchymal stem cells (MSCs), they can play a vital role in several different types of research applications including cell differentiation and gene regulation, gene therapy and transplantation, and cell-based screening assays in drug discovery. Cell Differentiation and Gene RegulationThe commitment of MSCs to a particular lineage is regulated by various signals from the cells' environment. Thus, there are many entry points into the process which can be exploited by researchers to help elucidate gene regulation and/or function. siRNA can be used to decrease the expression of a protein and allow one to better determine the function of the protein and pathways involved. Using stem cells allows one to study protein function and regulation at different stages in differentiation. Gene Therapy and Transplantation Mesenchymal stem cells have the potential to treat a wide range of diseases. Compared to other types of stem cells, MSCs have the ability to take up and keep introduced genes, a phenomenon that could be exploited for the delivery of … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Human Mesenchymal Stem Cells & Media

BCLI Gets A Pat On The Back, OXGN At Work, MDGN Rises After Hours

Posted: Published on October 9th, 2014

BrainStorm Cell Therapeutics Inc. (BCLI: Quote) has secured FDA's Fast Track product designation for its core technology, NurOwn, which is currently being studied in a randomized, double-blind, placebo-controlled phase II clinical trial in amyotrophic lateral sclerosis patients. The NurOwn technology processes adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many other cell types. BCLI closed Tuesday's trading at $3.98, up 2.84%. OXiGENE Inc. (OXGN: Quote) has enrolled the first patient in a phase 1b/2 clinical study that will evaluate its drug candidate Fosbretabulin in combination with GlaxoSmithKline PLC's (GSK) approved cancer medication Votrient in patients with recurrent ovarian cancer. The study is estimated to enroll up to 128 patients at sites in the United Kingdom. The primary endpoint is progression-free survival, and secondary endpoints include safety, overall survival, objective response rate and relevant biomarkers. OXGN closed Tuesday's trading 6.88% higher at $2.33. Medgenics Inc. (MDGN: Quote) is all set to present initial data from its ongoing phase 1/2 clinical trial of MDGN-201 at the 22nd Annual Congress of the European Society of Gene and Cell Therapy being held in The Hague, Netherlands from October 23rd-26th, 2014. The … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on BCLI Gets A Pat On The Back, OXGN At Work, MDGN Rises After Hours

BioEden the specialist tooth stem cell bank plan to shake up public perception as Stem Cell Awareness week takes hold.

Posted: Published on October 7th, 2014

(PRWEB UK) 7 October 2014 Stem cell treatments take place in countries all around the world every day. Thousands of lives have already been saved, and advancements in this area of medicine means that future healthcare treatments look set to further prolong and improve life. But specialist stem cell bank BioEden warn that there is a risk of thinking of stem cell therapy in terms of the future alone. 'The need to have a stem cell match is vital', says Group CEO Mr Tony Veverka. 'Without access to a stem cell match, the work of stem cell scientists could be at risk. That is the reason why BioEden was set up, to ensure that anyone could bank and have access to their own stem cells. We also wanted to ensure that the brilliant work being carried out by stem cell scientists and medical professionals could continue unhindered'. BioEden's services are being promoted by Health Care Professionals including specialist insurance intermediaries, and dentists. This week to highlight Stem Cell Awareness week, members of their specialist teams will be on the road visiting dentists, schools and healthcare insurance companies. 'Let's make everyone aware of the opportunities they have to store their own … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on BioEden the specialist tooth stem cell bank plan to shake up public perception as Stem Cell Awareness week takes hold.

New technique allows scientists to find rare stem cells within bone marrow

Posted: Published on October 7th, 2014

PUBLIC RELEASE DATE: 6-Oct-2014 Contact: Sarah McDonnell s_mcd@mit.edu 617-253-8923 Massachusetts Institute of Technology @MITnews CAMBRIDGE, MA -- Deep within the bone marrow resides a type of cells known as mesenchymal stem cells (MSCs). These immature cells can differentiate into cells that produce bone, cartilage, fat, or muscle a trait that scientists have tried to exploit for tissue repair. In a new study that should make it easier to develop such stem-cell-based therapies, a team of researchers from MIT and the Singapore-MIT Alliance in Research and Technology (SMART) has identified three physical characteristics of MSCs that can distinguish them from other immature cells found in the bone marrow. Based on this information, they plan to create devices that could rapidly isolate MSCs, making it easier to generate enough stem cells to treat patients. Until now, there has been no good way to separate MSCs from bone marrow cells that have already begun to differentiate into other cell types, but share the same molecules on the cell surface. This may be one reason why research results vary among labs, and why stem-cell treatments now in clinical trials are not as effective as they could be, says Krystyn Van Vliet, an MIT associate … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on New technique allows scientists to find rare stem cells within bone marrow

Stem cell therapy of a dog in the Netherlands. – Video

Posted: Published on October 5th, 2014

Stem cell therapy of a dog in the Netherlands. One a half years later he is juming and playing after first almost not being able not walk anymore. info@fat-stem.com. By: Fat Stem NV … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Stem cell therapy of a dog in the Netherlands. – Video

Dr. Raj Live – Stem Cell Therapy – Video

Posted: Published on October 5th, 2014

Dr. Raj Live - Stem Cell Therapy Dr. Raj discusses benefits of stem cell therapy. By: SPORTSDOC RAJ … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Dr. Raj Live – Stem Cell Therapy – Video

Page 30«..1020..29303132..4050..»

We cordially invite you to collaborate with us (as Speaker/Exhibitor/Sponsor/Media Partner) for “10th Annual Conference on Stem Cell and Regenerative Medicine” scheduled on August 13-14, 2018 in London, UK.

For meeting details visit: https://stemcell-regenerativemedicine.conferenceseries.com/